Pacific Edge revenues up, cash costs down on reorganisation
Join our daily newsletter At The Bell to receive exclusive market insights Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a …